Lupin receives USFDA's approval for generic Clobex Spray

27 Mar 2018 Evaluate

Lupin has received final approval for its Clobetasol Propionate Spray, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of Galderma Laboratories, L.P.'s Clobex Spray, 0.05%.

Clobetasol Propionate Spray, 0.05% had annual sales of around $30.5 million in the US (IQVIA MAT January 2018).

Lupin's Clobetasol Propionate Spray, 0.05% is the generic equivalent of Galderma Laboratories, L.P.'s Clobex Spray, 0.05%. It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×